Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.44 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 12/20 | 0.43 |
| ▸ | NPC1 | O15118 | 10/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | RARG | P13631 | 1/20 | 0.41 |
| ▸ | RXRA | P19793 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3186273 | 0.77 | SMN1; SMN2 (0.49) | HSP90AA1HSP90AB1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL9056564 | 0.73 | CRHBP (0.54) | RAB9ANPC1SMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL30149935 | 0.73 | RAB9A (0.52) | RAB9ANPC1SMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL4122541 | 0.73 | RAB9A (0.52) | RAB9ANPC1SMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL2733495 | 0.72 | SMN1; SMN2 (0.65) | HSP90AA1HSP90AB1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL18471517 | 0.71 | RAB9A (0.56) | RAB9ANPC1SMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL23617930 | 0.70 | MAPT (0.54) | HSP90AA1RAB9ANPC1SMN1; SMN2HPGD | |
| SCHEMBL18175926 | 0.70 | HPGD (0.50) | SMN1; SMN2ALDH1A1HPGDKDM4ELMNA | |
| SCHEMBL26152348 | 0.70 | RAB9A (0.48) | HSP90AA1HSP90AB1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL3193999 | 0.69 | ALOX15 (0.48) | RAB9ANPC1SMN1; SMN2ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1904494-B1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS VEGF-R2 INHIBITORS | LILLY CO ELI (US) | 2010-12-01 | — | — | EP | disclosed |
| US-7666879-B2 | Imidazo[1,2-A]pyridine compounds as VEGF-R2 inhibitors | ELI LILLY AND COMPANY (US) | 2010-02-23 | — | — | US | disclosed |
| US-20090227622-A1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS VEGF-R2 INHIBITORS | ELI LILLY AND COMPANY | 2009-09-10 | — | — | US | disclosed |
| EP-1904494-A1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS VEGF-R2 INHIBITORS | ELI LILLY AND COMPANY (US) | 2008-04-02 | — | — | EP | disclosed |
| WO-2006091671-A1 | IMIDAZO (1, 2-A) PYRIDINE COMPOUNDS AS VEGF-R2 INHIBITORS | ELI LILLY AND COMPANY (US) | 2006-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227622-A1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS VEGF-R2 INHIBITORS | KDR, FLT1, FLT4 | HSP90AA1 1905/4885HSP90AB1 1704/4885RAB9A 2607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.